LipAD™ - Proprietary Lipid-Assembled Drug Delivery Platforms 


TLC is committed to creating solutions for longstanding challenges in drug development by enabling new therapies with entirely unique properties.

LipAD™ allows the design of medicines at the nanometer scale, improving drug solubility, protecting molecules from degradation, or targeting drug delivery to specific tissues and compartments within a cell, creating drugs that are longer lasting with increased efficacy, and enabling new mechanisms that would otherwise be impractical.

These lipid-based technologies enable straightforward development of new formulations of well-known drugs by improving upon their clinical characteristics.

Prolonging Duration of Effect: BioSeizer™ Technology

Many different types of drugs are quickly metabolized and removed from circulation, limiting the duration of their effect following a single dose. Frequent dosing may compensate for a short duration of effect, but this is not always a good solution. Frequent dosing of drugs delivered by injection can be inconvenient, painful and carries an increased risk of infection.

Our proprietary BioSeizer™ technology entraps drugs to control the rate at which a therapeutic molecule is released from a lipid nanoparticle once in the body. BioSeizer™ nanoparticles consist of a drug wrapped within multiple layers of lipid membrane, precisely designed to release the drug at a constant rate as each layer collapses over time. This technology can be applied to a wide range of molecular payloads, including biologics, small molecules and oligonucleotides. Our technology for sustained release has advantages in many applications.

We are developing several new therapies using BioSeizer™, including TLC599 for osteoarthritis, TLC399 for the treatment of eye diseases, and TLC590 for postsurgical pain.

More on BioSeizer™